338 related articles for article (PubMed ID: 30672608)
1. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases.
Han M; Jung YS; Cheon JH; Park S
J Gastroenterol Hepatol; 2019 Jul; 34(7):1166-1174. PubMed ID: 30672608
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study.
Jung YS; Han M; Kim WH; Park S; Cheon JH
Dig Dis Sci; 2017 Aug; 62(8):2102-2112. PubMed ID: 28593437
[TBL] [Abstract][Full Text] [Related]
3. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
4. International variation in medication prescription rates among elderly patients with inflammatory bowel disease.
Benchimol EI; Cook SF; Erichsen R; Long MD; Bernstein CN; Wong J; Carroll CF; Frøslev T; Sampson T; Kappelman MD
J Crohns Colitis; 2013 Dec; 7(11):878-89. PubMed ID: 23018106
[TBL] [Abstract][Full Text] [Related]
5. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.
Rencz F; Péntek M; Bortlik M; Zagorowicz E; Hlavaty T; Śliwczyński A; Diculescu MM; Kupcinskas L; Gecse KB; Gulácsi L; Lakatos PL
World J Gastroenterol; 2015 Feb; 21(6):1728-37. PubMed ID: 25684937
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
Everhov ÅH; Halfvarson J; Myrelid P; Sachs MC; Nordenvall C; Söderling J; Ekbom A; Neovius M; Ludvigsson JF; Askling J; Olén O
Gastroenterology; 2018 Feb; 154(3):518-528.e15. PubMed ID: 29102619
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
[No Abstract] [Full Text] [Related]
8. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
9. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
Zhao M; Lirhus S; Lördal M; Langholz E; Knudsen T; Voutilainen M; Høivik ML; Moum B; Anisdahl K; Saebø B; Haiko P; Malmgren C; Coskun M; Melberg HO; Burisch J
Aliment Pharmacol Ther; 2022 Sep; 56(6):989-1006. PubMed ID: 35902223
[TBL] [Abstract][Full Text] [Related]
11. Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort.
Lujan R; Buchuk R; Focht G; Yogev D; Greenfeld S; Ben-Tov A; Weisband YL; Lederman N; Matz E; Ben Horin S; Dotan I; Nevo D; Turner D
Gastroenterology; 2024 May; 166(5):815-825.e22. PubMed ID: 38331205
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
Jeuring SFG; Biemans VBC; van den Heuvel TRA; Zeegers MP; Hameeteman WH; Romberg-Camps MJL; Oostenbrug LE; Masclee AAM; Jonkers DMAE; Pierik MJ
Am J Gastroenterol; 2018 Mar; 113(3):384-395. PubMed ID: 29317770
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center.
Kyriakos N; Papaefthymiou A; Giakoumis M; Galanopoulos M; Galanis P; Mylonas I; Karatzas P; Mantzaris G; Liatsos C
Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):153-160. PubMed ID: 33653987
[TBL] [Abstract][Full Text] [Related]
14. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
Mao EJ; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 Jan; 45(1):3-13. PubMed ID: 27862107
[TBL] [Abstract][Full Text] [Related]
15. Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013).
Blotière PO; Rudant J; Barré A; Racine A; Weill A; Peyrin-Biroulet L; Carbonnel F; Alla F
Dig Liver Dis; 2016 Jun; 48(6):620-5. PubMed ID: 27017107
[TBL] [Abstract][Full Text] [Related]
16. Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
Seishima R; Okabayashi K; Ikeuchi H; Uchino M; Futami K; Noguchi T; Ohge H; Iseki Y; Watanabe K; Itabashi M; Okamoto K; Toiyama Y; Ogino T; Nakamura M; Yamada K; Wakai T; Sato Y; Kimura H; Takahashi K; Hida K; Kinugasa Y; Ishida F; Okuda J; Daito K; Koyama F; Ueno H; Yamamoto T; Yamamoto S; Hanai T; Maemoto A; Arakaki J; Komori K; Akagi Y; Shida D; Yamaguchi S; Matsuda K; Maeda K; Noake T; Nezu R; Sasaki S; Hasegawa J; Sunami E; Kanemitsu Y; Katsumata K; Uehara K; Kiyomatsu T; Suto T; Kazama S; Yamada T; Goi T; Ishihara S; Ajioka Y; Sugihara K
Am J Gastroenterol; 2023 Jul; 118(7):1248-1255. PubMed ID: 36622356
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014: an analysis of nationwide databases.
Holko P; Kawalec P; Stawowczyk E
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):456-464. PubMed ID: 29256907
[TBL] [Abstract][Full Text] [Related]
18. Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014.
Larsen L; Drewes AM; Broberg MCH; Fallingborg J; Jacobsen BA; Jensen TB; Jess T
Inflamm Bowel Dis; 2018 Jan; 24(2):433-439. PubMed ID: 29361095
[TBL] [Abstract][Full Text] [Related]
19. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
[TBL] [Abstract][Full Text] [Related]
20. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
Alulis S; Vadstrup K; Olsen J; Jørgensen TR; Qvist N; Munkholm P; Borsi A
BMC Health Serv Res; 2021 Aug; 21(1):836. PubMed ID: 34407821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
